| Author/Editor | Hochmair, Maximilian J; Morabito, Alessandro; Hao, Desiree; Yang, Cheng-Ta; Soo, Ross A; Yang, James C-H; Gucalp, Rasim; Halmos, Balazs; Wang, Lara; Märten, Angela; Čufer, Tanja | |
| Title | Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer | |
| Type | članek | |
| Vol. and No. | Letnik 15, št. 25 | |
| Publication year | 2019 | |
| Volume | str. 2905-2914 | |
| ISSN | 1744-8301 - Future oncology (London, England) | |
| Language | eng | |
| Abstract | Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. | |
| Descriptors | Carcinoma, non-small cell lung Drug therapy Afatinib Nedrobnocelični karcinom pljuč Terapija z zdravili Afatinib Therapy Terapija | |
| Keywords | osimertinib raziskava GioTag osimertinib GioTag study |